Knight Therapeutics Inc.
KHTRF
$3.95
-$0.0924-2.29%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 270.92M | 256.26M | 249.38M | 246.46M | 243.29M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 270.92M | 256.26M | 249.38M | 246.46M | 243.29M |
| Cost of Revenue | 143.57M | 132.59M | 128.75M | 132.51M | 130.14M |
| Gross Profit | 127.35M | 123.68M | 120.63M | 113.95M | 113.15M |
| SG&A Expenses | 72.50M | 68.33M | 66.79M | 64.63M | 62.05M |
| Depreciation & Amortization | 32.39M | 32.96M | 33.32M | 33.19M | 33.38M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 265.43M | 248.72M | 243.49M | 243.94M | 238.58M |
| Operating Income | 5.49M | 7.54M | 5.89M | 2.52M | 4.72M |
| Income Before Tax | 1.29M | -23.55M | -17.37M | -17.73M | -16.09M |
| Income Tax Expenses | -1.65M | -945.40K | -1.84M | -5.00M | -3.81M |
| Earnings from Continuing Operations | 2.94 | -22.61 | -15.52 | -12.73 | -12.27 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.94M | -22.61M | -15.52M | -12.73M | -12.27M |
| EBIT | 5.49M | 7.54M | 5.89M | 2.52M | 4.72M |
| EBITDA | 40.99M | 42.16M | 40.90M | 36.96M | 39.50M |
| EPS Basic | 0.03 | -0.22 | -0.15 | -0.13 | -0.12 |
| Normalized Basic EPS | 0.09 | 0.02 | 0.06 | 0.06 | 0.07 |
| EPS Diluted | 0.02 | -0.22 | -0.16 | -0.13 | -0.13 |
| Normalized Diluted EPS | 0.09 | 0.02 | 0.06 | 0.06 | 0.07 |
| Average Basic Shares Outstanding | 404.17M | 407.35M | 412.47M | 419.62M | 429.96M |
| Average Diluted Shares Outstanding | 404.58M | 407.35M | 412.73M | 420.08M | 430.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |